Biologic Serialization Mandates.

Biologic serialization mandates

Introduction

Biologic serialization mandates refer to legal and regulatory requirements for assigning unique identification codes to individual packages of biological medicines so that they can be tracked throughout the pharmaceutical supply chain. These requirements help prevent counterfeit medicines, unauthorised distribution, product diversion and the circulation of substandard biological products.

Biological medicines include vaccines, monoclonal antibodies, recombinant proteins, blood-derived products and other medicines manufactured using biological systems. Since many biologics require specialised storage and transportation conditions, traceability is particularly important for maintaining product quality and patient safety.

Serialization generally involves assigning a unique product identifier to a saleable package and recording relevant information in a traceability system. It should be distinguished from ordinary batch identification: batch numbers identify groups of products, whereas serialization enables identification of individual saleable packages.

In India, there is no separate comprehensive statute exclusively governing serialization of all biological medicines. Requirements arise from pharmaceutical labelling regulations, manufacturing standards, traceability policies and applicable export-market regulations.

Legal framework governing biologic serialization in India

The Drugs and Cosmetics Act, 1940, provides the principal statutory framework for regulating the manufacture, distribution, sale and import of medicines.

The Drugs Rules, 1945, establish requirements concerning drug labelling, packaging, manufacturing and quality control.

Rule 96 deals with labelling requirements for drugs, while Rule 97 addresses additional labelling requirements for certain categories of drugs.

For specified pharmaceutical products, the Indian regulatory framework has introduced barcode or QR-code requirements to improve traceability and verification. However, these requirements should not be interpreted as a universal individual-package serialization mandate applying identically to every biological medicine.

The Drugs (Eighth Amendment) Rules, 2022, introduced amendments relating to QR-code requirements for specified active pharmaceutical ingredients. Such requirements are distinct from serialization of every finished biologic package.

The Schedule M requirements under the Drugs Rules establish Good Manufacturing Practices obligations. These support manufacturing documentation, batch identification, quality control and traceability.

Objectives of biologic serialization

Serialization serves several important regulatory and public-health purposes.

1. Counterfeit medicine prevention

Biological medicines may be expensive and technologically complex to manufacture. Unique identifiers can help verify product authenticity and identify suspicious or unauthorised products.

2. Supply-chain transparency

Serialization allows manufacturers, distributors and other authorised supply-chain participants to maintain records concerning product movement.

3. Product recall management

If a manufacturing defect or safety concern is identified, traceability information can help locate affected products and support targeted recalls.

4. Patient safety

Accurate product identification reduces the risk of dispensing errors and helps healthcare institutions verify medicine information.

5. Regulatory accountability

Serialization records can support regulatory inspections, investigations and compliance audits.

Serialization requirements in international markets

India exports biological medicines to several international markets. Consequently, Indian manufacturers may need to comply with additional serialization requirements when exporting products.

The United States has the Drug Supply Chain Security Act (DSCSA), 2013, which establishes requirements for product identification, tracing and verification of covered prescription drugs.

The European Union has adopted the Falsified Medicines Directive 2011/62/EU and Commission Delegated Regulation (EU) 2016/161. These establish safety-feature requirements for covered medicinal products, including unique identifiers and anti-tampering devices.

The applicability of these international requirements depends on the product, destination market and relevant exemptions. They should not automatically be treated as Indian domestic legal obligations.

Technical and operational compliance

Biologic serialization requires coordination between manufacturing, packaging, distribution and information-management systems.

Important compliance activities include:

Assigning unique identification codes where required.

Maintaining product and batch identification records.

Recording packaging and distribution information.

Integrating traceability systems with manufacturing operations.

Preventing duplication or unauthorised reuse of identifiers.

Maintaining reliable product verification procedures.

Supporting investigations and recalls through accurate records.

Serialization systems should also preserve the accuracy and security of electronic records.

The Information Technology Act, 2000, may become relevant where unauthorised access, manipulation or destruction of digital traceability records occurs.

The Bharatiya Sakshya Adhiniyam, 2023, particularly Sections 61–63, governs the evidentiary treatment of electronic and digital records in legal proceedings.

Regulatory liability for non-compliance

Failure to comply with applicable pharmaceutical labelling, manufacturing or traceability requirements may lead to regulatory consequences.

Under the Drugs and Cosmetics Act, 1940, Sections 17, 17A and 17B address misbranded, adulterated and spurious drugs respectively.

Section 18 restricts specified activities involving drugs that violate statutory requirements. Section 27 provides penalties for certain offences involving manufacture, sale and distribution of non-compliant drugs.

However, the absence of a serialization code does not automatically make every biological medicine a spurious drug. Authorities must establish the relevant statutory violation and applicable legal requirements.

Manufacturers may also face contractual liability, product-related claims and regulatory consequences in export markets.

Important judicial decisions

There are no widely recognised Supreme Court judgments in India directly deciding biologic serialization mandates. Nevertheless, several decisions provide relevant principles concerning pharmaceutical regulation, product authenticity and consumer protection.

1. Novartis AG v. Union of India (2013)

The Supreme Court examined pharmaceutical patentability under Section 3(d) of the Patents Act, 1970. Although the case did not concern serialization, it demonstrates the importance of statutory compliance and regulatory distinctions in pharmaceutical innovation.

2. Vincent Panikurlangara v. Union of India (1987)

The Supreme Court discussed the importance of protecting public health through appropriate pharmaceutical regulation. Its reasoning supports strict regulatory oversight of medicines entering the market.

3. Cadila Healthcare Ltd. v. Cadila Pharmaceuticals Ltd. (2001)

The Supreme Court considered the risk of confusion between pharmaceutical product names and emphasised the importance of preventing confusion in medicine-related commercial activity.

The decision is relevant by analogy to product identification and the need for reliable medicine verification.

4. M/s. Laxmi Engineering Works v. P.S.G. Industrial Institute (1995)

The Supreme Court examined consumer-protection principles concerning defective goods and commercial transactions. Its broader reasoning may be relevant to disputes involving pharmaceutical products and commercial responsibilities.

5. Indian Medical Association v. V.P. Shantha (1995)

The Supreme Court considered the applicability of consumer protection law to medical services. Its principles are relevant when pharmaceutical traceability failures contribute to deficient healthcare services.

These judgments provide related legal principles rather than direct judicial authority establishing serialization obligations.

Conclusion

Biologic serialization mandates are important for ensuring pharmaceutical authenticity, supply-chain transparency, effective product recalls and patient safety. In India, the regulatory foundation includes the Drugs and Cosmetics Act, 1940, Drugs Rules, 1945, and applicable manufacturing, labelling and traceability requirements.

International frameworks such as the United States DSCSA and European Union Falsified Medicines Directive also influence Indian manufacturers exporting biological medicines.

Serialization compliance must be assessed according to the specific product, packaging category, destination market and applicable regulatory requirements. A more comprehensive domestic traceability framework for biological medicines could strengthen counterfeit prevention, regulatory monitoring and pharmaceutical supply-chain accountability.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT